FDA Reverses ODAC Vote and Approves Panobinostat for Relapsed Myeloma - Read Dr. Durie's blog

The US Food and Drug Administration (FDA) on Monday approved panobinostat for the treatment of myeloma. Marketed by Novartis under the name Farydak, panobinostat is an HDAC inhibitor intended for patients who have received at least two prior therapies. The safety and efficacy of panobinostat, which is used in combination with bortezomib and dexamethasone, was demonstrated in 193 clinical trial participants. "The approval is obviously good news for the myeloma community," IMF Chairman Dr. Brian Durie reports in his blog.
Source: International Myeloma Foundation - Category: Hematology Source Type: news